A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.
- DOI
- 10.1002/ijc.33997
- Published
- 2022 Jun 1
- Container
- International journal of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/ijc.33997,
title = {A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.},
author = {Maille E and Levallet J and Dubois F and Antoine M and Danel C and Creveuil C and Mazieres J and Margery J and Greillier L and Gounant V and Moro-Sibilot D and Molinier O and Léna H and Monnet I and Bergot E and Langlais A and Morin F and Scherpereel A and Zalcman G and Levallet G},
year = {2022},
journal = {International journal of cancer},
doi = {10.1002/ijc.33997},
url = {https://doi.org/10.1002/ijc.33997}
}RIS
TY - JOUR TI - A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial. AU - Maille E AU - Levallet J AU - Dubois F AU - Antoine M AU - Danel C AU - Creveuil C AU - Mazieres J AU - Margery J AU - Greillier L AU - Gounant V AU - Moro-Sibilot D AU - Molinier O AU - Léna H AU - Monnet I AU - Bergot E AU - Langlais A AU - Morin F AU - Scherpereel A AU - Zalcman G AU - Levallet G PY - 2022 JO - International journal of cancer DO - 10.1002/ijc.33997 UR - https://doi.org/10.1002/ijc.33997 ER -
APA
E, M., J, L., F, D., M, A., C, D., C, C., J, M., J, M., L, G., V, G., D, M., O, M., H, L., I, M., E, B., A, L., F, M., A, S., G, Z., & G, L. (2022). A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.. International journal of cancer. https://doi.org/10.1002/ijc.33997
Source records
- pubmed · retrieved 2026-09-27T10:23:17.750Z